ACOG

NYC HEALTH + HOSPITALS DEBUTS OBSTETRICS VIRTUAL REALITY TECHNOLOGY AS PART OF ITS ONGOING, COMPREHENSIVE MATERNAL HEALTH SIMULATION TRAININGS

Retrieved on: 
Jeudi, juin 16, 2022
Time, RN, FACOG, Mortality, MBA, CHSE, Technology, Human, The Hindu Metroplus Theater Fest, Parent, NYC Health + Hospitals, Student, LinkedIn, Black and Brown!, Harriet Campbell-Taylor House, Curriculum, Disease, Nursing, Shoulder dystocia, Obstetrics, Hospital, FACS, Travel, New York City Department of Health and Mental Hygiene, Family, New Yorkers, Internal bleeding, Korea Disease Control and Prevention Agency, Virtual reality, Color, Workforce, Health, New, Twitter, Patient, Facebook, MPH, Communication, ACOG, Center, Medicine, Birth control, Gynaecology, City, MD, VR

NEW YORK and WESTMINSTER, Colo., June 16, 2022 /PRNewswire/ -- NYC Health + Hospitals and Health Scholars today announced the introduction of new virtual reality (VR) technology to NYC Health + Hospitals' course library of obstetrics (OB) simulation trainings. Co-developed with Health Scholars, a provider of innovative VR healthcare simulations, OB providers across the City's health care system will be able to hone in on skills to earlier detect and successfully address rare but life-threatening health conditions that can present during labor and delivery. The new VR technology will complement the training OB providers, including attendings, midwives, physician assistants, and residents, received from in-person training to experience simulated life-like scenarios through a VR headset, improving competencies and promoting knowledge retention at their convenience during shifts. The new VR OB training technology builds on the municipal health care system's commitment to combatting maternal mortality disparities present among people of color, often perpetuated by implicit bias.

Key Points: 
  • NEW YORK and WESTMINSTER, Colo., June 16, 2022 /PRNewswire/ -- NYC Health + Hospitals and Health Scholars today announced the introduction of new virtual reality (VR) technology to NYC Health + Hospitals' course library of obstetrics (OB) simulation trainings.
  • "I am excited to see NYC Health + Hospitals leveraging technology in service and support their obstetricians and the New Yorkers they serve.
  • "I am proud to say that NYC Health + Hospitals is a leader in virtual reality simulation training," said NYC Health + Hospitals Chief Women's Health Officer Wendy Wilcox, MD, MPH, MBA, FACOG.
  • Co-developers, Health Scholars, partnered with NYC Health + Hospitals due to the municipal health care system's comprehensive and high-tech approach to OB simulation trainings.

Alpha Cognition Announces Successful Defense of European Patent Covering ALPHA-0602

Retrieved on: 
Mercredi, juin 15, 2022
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Rivastigmine, Amyotrophic lateral sclerosis, Industry, FDA, COVID-19, Cognition, TSX, Neuron, OTC Markets Group, Technology, Motor neuron disease, Company, Neurodegeneration, Donepezil, Alzheimer's disease, Growth, Disease, Central nervous system, Advertising, Failure, News, European Patent Office, Memantine, TSX Venture Exchange, Organic acid, Patient, Terminology, IP, ACOG, Growth hacking, European Patent Convention, ALS, Pharmaceutical industry

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announces that the European Patent Office has confirmed the patentability of EP3009143 in amended form following an opposition proceeding involving two opponents.

Key Points: 
  • Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announces that the European Patent Office has confirmed the patentability of EP3009143 in amended form following an opposition proceeding involving two opponents.
  • This claim scope complements the granted European patent EP2249861 directed to treatment of Alzheimers and Parkinsons Disease with progranulin polypeptides and nucleic acids.
  • The successful defense of EP3009143 further supports ACOGs exclusively licensed IP portfolio relating to Progranulin, which includes granted patents and pending applications in Canada, China, India, Japan and the United States.
  • The issued patents demonstrate our commitment to developing ALPHA-0602, which is currently in pre-clinical studies for potential treatment of the motor neuron degeneration associated with ALS, said Michael McFadden, Chief Executive Officer of Alpha Cognition.

Alpha Cognition Announces Positive Data from Pre-Clinical Studies and Discovery of GEM Combinations with Potential for Neurodegenerative Disease Treatment

Retrieved on: 
Lundi, juin 13, 2022
Mental Health, Health, Stem Cells, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, FTD, Alzheimer's disease, OTC Markets Group, Company, Cognition, Survival, ACOG, Toxicity, Amyotrophic lateral sclerosis, Central nervous system, Forward-looking statement, FUS, Pathology, Neurodegeneration, ALPHA, News, Disease, Inflammation, Rivastigmine, Failure, Motor neuron, Therapy, Growth hacking, Memantine, FDA, Growth, Patient, Advertising, Gemstone, Technology, ALS, COVID-19, TSX, ACI, Industry, Cathepsin D, GEM, Granulin, Donepezil, TSX Venture Exchange, SMA, Terminology, Pharmaceutical industry, Frankincense, Aroma compound, Dietary supplement

ALPHA-0702 and ALPHA-0802 are Granulin Epithelin Motifs, or GEMs, derived from full length progranulin (PGRN) which have therapeutic potential across multiple neurodegenerative diseases.

Key Points: 
  • ALPHA-0702 and ALPHA-0802 are Granulin Epithelin Motifs, or GEMs, derived from full length progranulin (PGRN) which have therapeutic potential across multiple neurodegenerative diseases.
  • These data underscore robust preclinical evidence supporting Alpha Cognitions approach to treating neurodegenerative disease and highlight the Companys strategy to validate these data in additional pre-clinical studies.
  • These benefits have been observed in preclinical studies and strongly support the continued development of both compounds for the treatment of neurodegenerative diseases.
  • This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

Alpha Cognition Announces Grant of Stock Options

Retrieved on: 
Mardi, mai 31, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Memantine, Company, Disease, Growth hacking, Amyotrophic lateral sclerosis, Dementia, OTC Markets Group, TSX, Neurodegeneration, Alzheimer's disease, Cognition, Central nervous system, Safety, Traumatic brain injury, Donepezil, TSX Venture Exchange, ACOG, Rivastigmine, ALS, Pharmaceutical industry

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, announces the grant of stock options pursuant to its stock option plan to certain directors of the Company to purchase up to an aggregate of 400,000 common shares of the Company.

Key Points: 
  • Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, announces the grant of stock options pursuant to its stock option plan to certain directors of the Company to purchase up to an aggregate of 400,000 common shares of the Company.
  • The stock options are exercisable at a price of $0.64 CAD per share and expire ten years from the date of grant, subject to certain vesting provisions.
  • Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS).
  • ALPHA-1062, is a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials.

Alpha Cognition Announces First Quarter 2022 Results and Company Update

Retrieved on: 
Mardi, mai 31, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, P-value, Memantine, Company, Disease, R, G&A, Research, Depreciation, Growth hacking, Amyotrophic lateral sclerosis, News, Transaction, File, Dementia, Advertising, Traumatic brain injury, OTC Markets Group, Concussion, USD, COVID-19, Failure, TSX, FDA, Neurodegeneration, Alzheimer's disease, Industry, Cognition, Spinal muscular atrophy, Terminology, Central nervous system, Safety, Technology, Donepezil, TSX Venture Exchange, NDA, ACOG, Acquisition, Rivastigmine, Growth, Patient safety, ALS, Pharmaceutical industry, Dietary supplement, Cryptocurrency

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2022.

Key Points: 
  • Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2022.
  • "Alpha Cognition reported positive preclinical data with ALPHA-1062 intranasal for mTBI and ALPHA-0602 for ALS during the first quarter of 2022 and continued to build-out our experienced leadership team.
  • The Company also plans to meet with the FDA for the ALPHA-1062 intranasal for mTBI during the third quarter of 2022.
  • During the second quarter of 2022, the company met with FDA regarding the ALPHA-1062 program for mild-to-moderate Alzheimers Disease.

SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA DEMONSTRATING IMPROVED PERFORMANCE OF ITS PRETRM® TEST WITH MORE PRECISE GESTATIONAL AGE

Retrieved on: 
Jeudi, mai 19, 2022
Physician, CPT, Death, Risk, Form, Company, Blood, Private Securities Litigation Reform Act, Seizure, Disease, U.S. Securities and Exchange Commission, Journal, Proteomics, PAPR, Patient, Woman, Hearing loss, NASDAQ, Health, Prospectus, Sumathi Best Television Current Reporting Award, Cerebral palsy, Premature, COVID-19, Mortality, Trial of the century, Gestational age, FDA, SALT, MS, Pregnancy, Learning, Biomarker, Medicine, Spontaneous, ACOG, Preterm birth, Protein, Security (finance), United, Intellectual disability, CEO, Birth control, Health insurance, Risk management, MD

SALT LAKE CITY, May 19, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication of improved PreTRM® test performance using women from the Proteomic Assessment of Preterm Risk (PAPR) clinical study whose pregnancy outcomes are aligned with updated ACOG gestational age dating guidelines. The newly published article reports:

Key Points: 
  • "A PreTRM test higher risk result reflects a similar risk as is revealed by traditional assessment techniques, but the PreTRM test identifies far more patients who are at risk of premature delivery.
  • The PreTRM test was developed and validated for prediction of spontaneous preterm birth broadly in the U.S. in the Proteomic Assessment of Preterm Risk (PAPR) study.
  • Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care.
  • Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc.in the United Statesand/or other countries.

epocrates Launches Innovative Long COVID-19 Tool and Incorporates Late-Breaking Updates to an Expanding Library of Clinical Decision Support Guidelines

Retrieved on: 
Mercredi, mai 18, 2022
Technology, Infectious Diseases, Diabetes, Practice Management, Other Health, Biotechnology, AIDS, General Health, Health, Data Management, Consensus, Diverticulitis, Severe acute respiratory syndrome coronavirus 2, Diabetes, Physician, Risk, Sex, Pre-exposure prophylaxis, Guideline, American College, American College of Gastroenterology, AGA, Patient, ESCP, Colonoscopy, Health, FACP, Nursing, COVID-19, American Diabetes Association, Research, FDA, ASCRS, ADA, Recurrence, Industry, Health care, Government, GERD, Society, Type 2 diabetes, ACG, Monoclonal antibody, PPI, Medical information, Decision-making, ACOG, Metformin, CDC, Centers for Disease Control and Prevention, HIV, Pharmacist, Center, Diagnosis, COVID, American College of Physicians, MD, Pharmaceutical industry, Medical device, Dietary supplement, Hyperglycemia

As the COVID-19 pandemic continues to evolve and new observational and trial data emerge, medical societies update their recommendations accordingly.

Key Points: 
  • As the COVID-19 pandemic continues to evolve and new observational and trial data emerge, medical societies update their recommendations accordingly.
  • In 2021, epocrates made more than 160 COVID-19 related updates, with at least 40 updates in Q4 2021 alone.
  • epocrates most recently launched decision tool, Long COVID-19 Eval & Management , focuses on the next phase of the pandemic, where the attention shifts to understanding the long-term effects of COVID.
  • Since 1998, epocrates, an athenahealth, Inc. company, has served essential, clinical content to more than one million physicians, nurses, pharmacists and other healthcare professionals.

SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting

Retrieved on: 
Mardi, mai 10, 2022
Vomiting, Birth, Mycosis, American College, QIDP, EMA, NASDAQ, GLOBE, Dizziness, ACOG, Pregnancy, Company, Biotechnology, Tablet, European Medicines Agency, Safety, Food, Diarrhea, Patient, CYP3A, Abdominal pain, Infection, Most, FDA, Incidence, Administration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, New Drug Application, FURI, Shanda, Candidiasis, Vaginal yeast infection, IV, Science, Drug of last resort, Fungemia, IC, IA, Thornburgh v. American College of Obstetricians & Gynecologists, Nausea, Pharmaceutical industry, Dietary supplement, Gynaecology, VVC

Data show that of the FURI study patients with refractory or relapsed vulvovaginal candidiasis (VVC) treated with ibrexafungerp, 71.4% had successful clinical outcomes.

Key Points: 
  • Data show that of the FURI study patients with refractory or relapsed vulvovaginal candidiasis (VVC) treated with ibrexafungerp, 71.4% had successful clinical outcomes.
  • The new interim analysis was presented during the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting held in San Diego on May 6-8, 2022.
  • We are extremely encouraged by these data showing positive outcomes in VVC patients with severe refractory or relapsed infections, said David Angulo, M.D., Chief Medical Officer of SCYNEXIS.
  • In the study, ibrexafungerp was generally safe and well-tolerated with findings consistent with the existing BREXAFEMME (ibrexafungerp tablets) label.

Renovia debuts "Stronger Women" campaign at annual gathering of women's health care leaders

Retrieved on: 
Vendredi, mai 6, 2022
PDT, Rehabilitation, Loneliness, American College, University, University of New Mexico, Instagram, Twitter, Femtech, Woman, ACOG, Smartphone, Physician, Massachusetts General Hospital, Shame, Research, PFMT, Use, Storey, Patient, Sexual dysfunction, ACSM, Obstetrics & Gynecology (journal), University of Alabama, Kegel exercise, FDA, Urinary incontinence, Therapy, M.D, Overactive bladder, Adult, Health, Randomized controlled trial, Movement, LinkedIn, Female, UI, Harvard Medical School, Science, Pelvic floor, CEO, SAN, Obstetrics, Obstetrics and gynaecology, All rights reserved, American College of Obstetricians and Gynecologists, Taboo, Digital, Birth control, Pharmaceutical industry, Gynaecology, Facebook

SAN DIEGO, May 6, 2022 /PRNewswire/ -- ACOG Annual Meeting — Renovia Inc. (Renovia), a women-led company that develops digital therapeutics for female pelvic floor disorders, has launched a new brand campaign titled, Stronger Women, at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting (ACSM). The campaign is intended to educate clinicians and women about urinary incontinence (UI) and the leva® Pelvic Health System, a convenient, easy-to-use, at-home pelvic health program that can help women strengthen their pelvic floor and decrease the symptoms of stress, mixed and mild to moderate UI, including overactive bladder. Through the campaign, and by launching it at the ACSM, Renovia seeks to make first-line treatment for UI more accessible and accelerate the momentum supporting regular screening for female UI among clinicians.

Key Points: 
  • The Stronger Women campaign centers on the importance of a strong pelvic floor in women's overall health and well-being.
  • The campaign also humanizes the issues associated with UI and, thus, seeks to make UI less taboo.
  • "While ACOG recommends annual screening for UI, treatment options often require drugs, surgery or access to physical therapy.
  • Renovia Inc. and levaare trademarks or registered trademarks of Renovia Inc. in the United States and other countries.

Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentation

Retrieved on: 
Jeudi, mai 5, 2022
Ethinylestradiol, Birth, CHC, LNG, Population, Nasdaq, Woman, GLOBE, ACOG, Company, Securities Exchange Act of 1934, Securities Act of 1933, Food, Safety, Smoke, Poster, United, Patient, Doctor of Philosophy, Șaeș, Clinical trial, Risk, Freedom, Annual report, Drug Quality and Security Act, Regulation of tobacco by the U.S. Food and Drug Administration, BMI, Prescription, FACOG, Kro (comics), Skin, Health, Levonorgestrel, TDS, MBA, Tobacco smoking, HCPS, U.S. Securities and Exchange Commission, Body mass index, Doctor of Pharmacy, Therapy, Medical device, Birth control, MD, Contraceptive patch

No venous thromboembolic events (VTEs) were reported, and two serious adverse events (SAEs) were reported, findings which are consistent with the safety profile reported in the SECURE study.

Key Points: 
  • No venous thromboembolic events (VTEs) were reported, and two serious adverse events (SAEs) were reported, findings which are consistent with the safety profile reported in the SECURE study.
  • These data from real-world use among a diverse US population further support the Twirla safety and tolerability profile established in the SECURE clinical trial, said Paul Korner, MD, MBA, Chief Medical Officer of Agile Therapeutics.
  • In addition to the safety findings, reports of TDS adhesion issues were rare, and only 14 individuals received a replacement patch over the 12-month period.
  • For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements.